Ablation of negative regulators that hinder TCR response in T cells not only promoted T cell activation but significantly enhanced T cell tumour-killing capabilities through pathways of MAPK (RASA2) [131], ubiquitination degradation (CBLB) [148], and JAK/STAT (SOCS1 and TCEB1) [149]. This evidence concerns the gene RASA2 and neoplasm.